ArticleThorax2012
Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry.
Article in Thorax, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03324230 (Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma- an Exploratory Study.), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma- an Exploratory Study.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.American journal of respiratory and critical care medicine · 2020Pooled it
- Costs of Oral Corticosteroid Use in Patients with Severe Asthma With/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry.Advances in therapy · 2025Article
- Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma.Patient preference and adherence · 2025Article
- Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK.NPJ primary care respiratory medicine · 2024Article
- Article
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- Benefits of specialist severe asthma management: demographic and geographic disparities.The European respiratory journal · 2022Article
- Biologics in severe asthma: the role of real-world evidence from registries.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Emerging Roles of Non-Coding RNAs in Childhood Asthma.Frontiers in pharmacology · 2022Review
- Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.Respirology (Carlton, Vic.) · 2021Review
- "Real-life" management of patients with severe asthma in the biologics era: Can we do better?The World Allergy Organization journal · 2021Article
- Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era.Thorax · 2021Article
- Treatment options in type-2 low asthma.The European respiratory journal · 2021Review
- The Management of Extrapulmonary Comorbidities and Treatable Traits; Obesity, Physical Inactivity, Anxiety, and Depression, in Adults With Asthma.Frontiers in allergy · 2021Review
- The Role of Quantification of Glucocorticoid-associated Toxicity in Severe Asthma.Journal of cellular immunology · 2021Article
- Article
- Rational oral corticosteroid use in adult severe asthma: A narrative review.Respirology (Carlton, Vic.) · 2020Review
- Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.Risk management and healthcare policy · 2020Article
- Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA).Journal of asthma and allergy · 2020Article
- Severe T2-high asthma in the biologics era: European experts' opinion.European respiratory review : an official journal of the European Respiratory Society · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.